We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App





Monoclonal Antibody Treatment Combination Reduces Hospitalization Among High-Risk COVID-19 Patients

By HospiMedica International staff writers
Posted on 31 Aug 2021
Print article
Illustration
Illustration
In an observational study, researchers have reported that the combination of casirivimab and imdevimab - two monoclonal antibody treatments under Food and Drug Administration emergency use authorization – can keep high-risk patients out of the hospital when infected with mild to moderate COVID-19.

In the study that enrolled nearly 1,400 patients from Mayo Clinic (Rochester, Minn., USA), 696 received the drug combo between December 2020 and early April and an equal matched cohort did not receive it. Their status was evaluated at 14, 21 and 28 days after treatment. At each point, the numbers for hospitalization were significantly lower in the treated group.

At Day 14, 1.3% of the treated group was in the hospital, compared to 3.3% of those who had not been treated. At Day 21, only 1.3% treated was hospitalized, compared to 4.2% of those who had not been treated. At the end of 28 days, 1.6% of those treated was hospitalized versus 4.8% of those who had not been treated. This translated to 60-70% relative reduction in hospitalization among treated patients. Of those who were subsequently hospitalized, the rates of ICU admission and mortality were low.

A previous Mayo Clinic study involving 2,335 treated patients between November of 2020 and February had suggested that the use of bamlanivimab reduced hospitalizations in high-risk patients by 40-60%. Comparing their outcomes with 2,335 untreated patients, the ICU admission and mortality rates also were significantly lower with monoclonal antibody treatment. It should be noted that the FDA in April had revoked the EUA for bamlanivimab alone and now endorses the use of combination monoclonal antibodies.

"Once again, this real-world study suggests that when patients who are at high risk due to a range of comorbidities contract a mild or moderate case of COVID-19, this combination of monoclonal injections gives them a chance of a non-hospitalized recovery. In other words, they recover safely at home," said Raymund Razonable, M.D., a Mayo Clinic infectious diseases specialist and senior author of the study. "Our conclusion overall at this point is that monoclonal antibodies are an important option in treatment to reduce the impact of COVID-19 in high-risk patients."

Related Links:
Mayo Clinic

Gold Supplier
Ultrasound Transducer/Probe Cleaner
Transeptic Cleaning Solution
New
Portable Finger Pulse Oximeter
Onyx Vantage 9590
New
Smart nCPAP Device
SVAAS nCPAP
New
Capnograph/Pulse Oximeter
Handleld Capnograph/Pulse Oximeter

Print article

Channels

AI

view channel
Image: A novel research study moves the needle on predicting coronary artery disease (Photo courtesy of Pexels)

AI-Enabled ECG Analysis Predicts Heart Attack Risk Nearly as well as CT Scans

Increased coronary artery calcium is a marker of coronary artery disease that can lead to a heart attack. Traditionally, CT scans are used to diagnose buildup of coronary artery calcium, although CT scanners... Read more

Critical Care

view channel
Image: The advanced electronic skin could enable multiplex healthcare monitoring (Photo courtesy of Terasaki Institute)

First-of-Its-Kind Electronic Skin Patch Enables Advanced Health Care Monitoring

For some time now, electronic skin (E-skin) patches have been used to monitor bodily physiological and chemical indicators of health. Such monitors, placed on the skin, are capable of measuring various... Read more

Surgical Techniques

view channel
Image: The neuro-chip with soft implantable electrodes could manage brain disorders (Photo courtesy of EPFL)

Implantable Neuro-Chip Uses Machine Learning Algorithm to Detect and Treat Neurological Disorders

Using a combination of low-power chip design, machine learning algorithms, and soft implantable electrodes, researchers have produced a neural interface that can identify and suppress symptoms of different... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: Researchers expect broader adoption of AI in healthcare in the near future (Photo courtesy of Pexels)

Artificial Intelligence (AI) Could Save U.S. Healthcare Industry USD 360 Billion Annually

The wider adoption of artificial intelligence (AI) in healthcare could save the U.S. up to USD 360 billion annually although its uptake in the industry is presently limited owing to the absence of trust... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.